# Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

> **NCT01031069** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 873 (actual)

## Conditions studied

- Infections, Papillomavirus
- Papillomavirus Vaccines

## Interventions

- **BIOLOGICAL:** GSK Biologicals' HPV vaccine 580299
- **BIOLOGICAL:** Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)

## Key facts

- **NCT ID:** NCT01031069
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-26
- **Primary completion:** 2016-01-13
- **Final completion:** 2017-04-19
- **Target enrollment:** 873 (ACTUAL)
- **Last updated:** 2020-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031069, "Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01031069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*